Abstract
The role of CD4+ T cells in the generation of therapeutic primary and memory immune responses in cancer diverse immunotherapy settings remains ambiguous. We herein investigated this issue using two vaccine formulations containing a novel costimulatory molecule, SA-4-1BBL, as adjuvant and HPV E7 or survivin (SVN) as tumor associated antigens (TAAs) in two mouse transplantable tumor models; the TC-1 cervical cancer expressing xenogeneic HPV E7 and 3LL lung carcinoma overexpressing autologous SVN. Single vaccination with optimized SA-4-1BBL/TAA formulations resulted in the eradication of 6-day established TC-1 and 3LL tumors in >70% of mice in both models. The in vivo depletion of CD4+ T cells one day before tumor challenge resulted in compromised vaccine efficacy in both TC-1 (25%) and 3LL (12.5%) tumor models. In marked contrast, depletion of CD4+ T cells 5 days post-tumor challenge and one day prior to vaccination did not significantly alter the therapeutic efficacy of these vaccines. However, long-term immunological memory was compromised in the 3LL, but not in TC-1 model as a significant number (85.7%) of tumor free-mice succumbed to tumor growth when rechallenged with 3LL cells 60 days after the initial tumor inoculation. Collectively, these results demonstrate the indispensable role CD4+ T cells play in the generation of therapeutic primary immune responses elicited by SA-4-1BBL/TAA-based vaccines irrespective of the nature of TAAs and establish the importance of CD4+ T cells for long-term immune memory against 3LL tumor expressing self-antigen SVN, but not TC-1 expressing xenogeneic viral antigen E7.
Highlights
The critical role of CD4+ T cells in the generation of effective and durable adaptive immune responses against various infections, such as intracellular parasites, bacteria, and viruses, has been well documented [1,2,3,4]
Optimization of SA-4-1BBL/E7 vaccine formulations for the most effective therapy in the TC-1 tumor model We have previously demonstrated that single immunization with a vaccine formulation containing 25 mg of SA-4-1BBL and 50 mg of E7 protein had,70% efficacy in the established TC-1 tumor model [25]
The success of tumor associated antigens (TAAs)-based vaccines hinges upon their ability to generate robust immune effector responses, and overcome various immune evasion mechanisms employed by the progressing tumor
Summary
The critical role of CD4+ T cells in the generation of effective and durable adaptive immune responses against various infections, such as intracellular parasites, bacteria, and viruses, has been well documented [1,2,3,4]. It is assumed that CD4+ T cells play a similar role in immune responses against tumors, which was substantiated by using autologous tumor-specific CD4+ T cells for adaptive immune therapy against cancer [5]. The role and relative contribution of CD4+ T cells to immune responses generated against cancer in vivo in response to active vaccination remains to be fully elucidated. Subsequent studies have demonstrated the helper function of
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
